Evidence on the clinical and cost effectiveness of molnupiravir is currently under review through the NICE multiple technology appraisal process.

Consider a 5-day course of molnupiravir for adults with COVID-19 who:

 

When assessing the person, take into account their likely response to any vaccinations already given, any comorbidities or risk factors, and whether their condition is deteriorating. 

This recommendation is informed by the results of the MOVe-OUT trial, which included only unvaccinated people. The trial ran before the emergence of the Omicron (B.1.1.529) variant. 

 

Adapted from NICE COVID-19 rapid guideline: Managing COVID-19 - Therapeutics for COVID-19